Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A prospective, cumulative study of testosterone-undecanoate in hypogonadal men : An Observational registry record study

Trial Profile

A prospective, cumulative study of testosterone-undecanoate in hypogonadal men : An Observational registry record study

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 03 Nov 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Testosterone undecanoate (Primary)
  • Indications Hypogonadism
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 25 Sep 2020 Results assessing effects of long-term therapy with testosterone on liver metabolism and MACE over 11 years in men with hypogonadism and type 2 diabetes, presented at the 56th Annual Meeting of the European Association for the Study of Diabetes
    • 18 Mar 2019 Results assessing the effect of Testosterone Undecanoate Injections in men with Hypogonadism and Osteoporosis (n=102), presented at the 101st Annual Meeting of the Endocrine Society
    • 05 Oct 2018 Results assessing long-term testosterone therapy in hypogonadal men with T2DM (n=311) presented at the 54th Annual Meeting of the European Association for the Study of Diabetes

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top